vs
Side-by-side financial comparison of Bunge Global (BG) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
Bunge Global is the larger business by last-quarter revenue ($4.9B vs $2.8B, roughly 1.7× Bausch Health Companies Inc.). Bunge Global runs the higher net margin — 1.9% vs -3.7%, a 5.6% gap on every dollar of revenue. On growth, Bunge Global posted the faster year-over-year revenue change (22.2% vs 9.3%). Bunge Global produced more free cash flow last quarter ($809.0M vs $403.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 11.3%).
Bunge Global SA (BUN-ghee) is a global agribusiness and food company, incorporated in Geneva, Switzerland and headquartered in St. Louis, Missouri, United States.
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
BG vs BHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.9B | $2.8B |
| Net Profit | $95.0M | $-103.0M |
| Gross Margin | 20.7% | — |
| Operating Margin | 1.8% | 17.0% |
| Net Margin | 1.9% | -3.7% |
| Revenue YoY | 22.2% | 9.3% |
| Net Profit YoY | -84.2% | -205.1% |
| EPS (diluted) | $-0.02 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.9B | $2.8B | ||
| Q3 25 | $4.4B | $2.7B | ||
| Q2 25 | $4.0B | $2.5B | ||
| Q1 25 | $3.7B | $2.3B | ||
| Q4 24 | $4.0B | $2.6B | ||
| Q3 24 | $3.9B | $2.5B | ||
| Q2 24 | $3.7B | $2.4B | ||
| Q1 24 | $3.9B | $2.2B |
| Q4 25 | $95.0M | $-103.0M | ||
| Q3 25 | $166.0M | $179.0M | ||
| Q2 25 | $354.0M | $148.0M | ||
| Q1 25 | $201.0M | $-58.0M | ||
| Q4 24 | $602.0M | $98.0M | ||
| Q3 24 | $221.0M | $-85.0M | ||
| Q2 24 | $70.0M | $10.0M | ||
| Q1 24 | $244.0M | $-64.0M |
| Q4 25 | 20.7% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 18.4% | — | ||
| Q1 25 | 16.3% | — | ||
| Q4 24 | 27.0% | — | ||
| Q3 24 | 19.9% | — | ||
| Q2 24 | 17.8% | — | ||
| Q1 24 | 22.2% | — |
| Q4 25 | 1.8% | 17.0% | ||
| Q3 25 | 6.2% | 23.1% | ||
| Q2 25 | 12.3% | 17.5% | ||
| Q1 25 | 7.8% | 12.2% | ||
| Q4 24 | 18.3% | 21.8% | ||
| Q3 24 | 8.3% | 12.7% | ||
| Q2 24 | 2.8% | 16.2% | ||
| Q1 24 | 9.4% | 13.1% |
| Q4 25 | 1.9% | -3.7% | ||
| Q3 25 | 3.8% | 6.7% | ||
| Q2 25 | 8.8% | 5.8% | ||
| Q1 25 | 5.5% | -2.6% | ||
| Q4 24 | 15.0% | 3.8% | ||
| Q3 24 | 5.7% | -3.4% | ||
| Q2 24 | 1.9% | 0.4% | ||
| Q1 24 | 6.2% | -3.0% |
| Q4 25 | $-0.02 | $-0.30 | ||
| Q3 25 | $0.84 | $0.48 | ||
| Q2 25 | $2.61 | $0.40 | ||
| Q1 25 | $1.48 | $-0.16 | ||
| Q4 24 | $4.27 | $0.24 | ||
| Q3 24 | $1.56 | $-0.23 | ||
| Q2 24 | $0.48 | $0.03 | ||
| Q1 24 | $1.68 | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $1.3B |
| Total DebtLower is stronger | $10.2B | $20.8B |
| Stockholders' EquityBook value | $15.9B | $-554.0M |
| Total Assets | $44.5B | $26.4B |
| Debt / EquityLower = less leverage | 0.64× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $3.2B | $1.3B | ||
| Q2 25 | $7.1B | $1.7B | ||
| Q1 25 | $3.9B | $1.1B | ||
| Q4 24 | $3.8B | $1.2B | ||
| Q3 24 | $3.0B | $719.0M | ||
| Q2 24 | $1.3B | $595.0M | ||
| Q1 24 | $3.1B | $733.0M |
| Q4 25 | $10.2B | $20.8B | ||
| Q3 25 | $11.1B | $21.0B | ||
| Q2 25 | $7.7B | $21.7B | ||
| Q1 25 | $5.4B | $21.5B | ||
| Q4 24 | $5.4B | $21.6B | ||
| Q3 24 | $5.4B | $21.5B | ||
| Q2 24 | $4.1B | $21.7B | ||
| Q1 24 | $4.1B | $22.1B |
| Q4 25 | $15.9B | $-554.0M | ||
| Q3 25 | $15.8B | $-565.0M | ||
| Q2 25 | $10.9B | $-764.0M | ||
| Q1 25 | $10.6B | $-1.2B | ||
| Q4 24 | $9.9B | $-1.3B | ||
| Q3 24 | $10.1B | $-1.2B | ||
| Q2 24 | $10.0B | $-1.2B | ||
| Q1 24 | $10.6B | $-1.1B |
| Q4 25 | $44.5B | $26.4B | ||
| Q3 25 | $46.3B | $26.8B | ||
| Q2 25 | $31.2B | $27.3B | ||
| Q1 25 | $26.7B | $26.4B | ||
| Q4 24 | $24.9B | $26.5B | ||
| Q3 24 | $25.3B | $26.5B | ||
| Q2 24 | $24.4B | $26.5B | ||
| Q1 24 | $25.8B | $26.9B |
| Q4 25 | 0.64× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.41× | — | ||
| Q1 24 | 0.39× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.3B | $495.0M |
| Free Cash FlowOCF − Capex | $809.0M | $403.0M |
| FCF MarginFCF / Revenue | 16.6% | 14.4% |
| Capex IntensityCapex / Revenue | 11.0% | 3.3% |
| Cash ConversionOCF / Net Profit | 14.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-879.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $495.0M | ||
| Q3 25 | $854.0M | $405.0M | ||
| Q2 25 | $-1.1B | $289.0M | ||
| Q1 25 | $-285.0M | $211.0M | ||
| Q4 24 | $1.1B | $601.0M | ||
| Q3 24 | $1.3B | $405.0M | ||
| Q2 24 | $-1.5B | $380.0M | ||
| Q1 24 | $994.0M | $211.0M |
| Q4 25 | $809.0M | $403.0M | ||
| Q3 25 | $385.0M | $314.0M | ||
| Q2 25 | $-1.5B | $190.0M | ||
| Q1 25 | $-595.0M | $96.0M | ||
| Q4 24 | $564.0M | $495.0M | ||
| Q3 24 | $973.0M | $334.0M | ||
| Q2 24 | $-1.8B | $302.0M | ||
| Q1 24 | $758.0M | $129.0M |
| Q4 25 | 16.6% | 14.4% | ||
| Q3 25 | 8.8% | 11.7% | ||
| Q2 25 | -36.8% | 7.5% | ||
| Q1 25 | -16.2% | 4.2% | ||
| Q4 24 | 14.1% | 19.3% | ||
| Q3 24 | 25.1% | 13.3% | ||
| Q2 24 | -47.4% | 12.6% | ||
| Q1 24 | 19.2% | 6.0% |
| Q4 25 | 11.0% | 3.3% | ||
| Q3 25 | 10.7% | 3.4% | ||
| Q2 25 | 10.1% | 3.9% | ||
| Q1 25 | 8.5% | 5.1% | ||
| Q4 24 | 12.2% | 4.1% | ||
| Q3 24 | 9.1% | 2.8% | ||
| Q2 24 | 8.0% | 3.2% | ||
| Q1 24 | 6.0% | 3.8% |
| Q4 25 | 14.18× | — | ||
| Q3 25 | 5.14× | 2.26× | ||
| Q2 25 | -3.03× | 1.95× | ||
| Q1 25 | -1.42× | — | ||
| Q4 24 | 1.75× | 6.13× | ||
| Q3 24 | 6.00× | — | ||
| Q2 24 | -21.06× | 38.00× | ||
| Q1 24 | 4.07× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BG
| Other Oilseeds Processing And Refining | $4.6B | 95% |
| Other | $251.0M | 5% |
| Other Products | $3.0M | 0% |
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
